A randomized controlled trial on the safety and efficacy of a modified regimen of photodynamic therapy with verteporfin on acute central serous chorioretinopathy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-05000639

Enrollment

Unknown

Registered

2005-09-08

Start date

2005-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Two groups:photodynamic therapy for 12 months vs observation

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged 18 years or older; VA with Snellen equivalent of >= 20/200; Greatest linear dimension of the entire lesion with ICG-A guidance must not exceed 5400 µm.

Exclusion criteria

Exclusion criteria: On exogenous corticosteroid Systemic diseases such as Cushing's disease or renal diseases of glomerulonephritis Pregnancy; Visual acuity worse than 20/200 in the affected eye; Myopia <= -6.00 diopters; Presence of any choroidal neovascularization or other maculopathy; Tear (rip) of the retinal pigment epithelium; A history of laser photocoagulation Ocular surgery in the recent 3 months Any contraindication for the verteporfin infusion or fluorescein or ICG injection.

Design outcomes

Primary

Measure	Time frame
Complete absorption of subretinal fluid;	—

Secondary

Measure	Time frame
electrophysiological results;	—

Countries

China

Contacts

Public ContactDr. Timothy Y.Y. Lai

eyeclinic@cuhk.edu.hk+852 27623134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026